Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Daré Bioscience Announces Efficacy Results From The DARE-HRT1 Phase 1 / 2 Study

Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause   DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both
byBenzinga Newsdesk
October 17, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause
 

DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

‘Chinese EV Start-Up Nio Makes Contingency Plans To Avoid Production Loss As Beijing Prepares To Exit Zero-Covid Strategy’

By Benzinga Newsdesk
December 12, 10:23 AM
https://www.scmp.com/business/china-business/article/3203051/chinese-ev-start-nio-makes-contingency-plans-avoid-production-loss-beijing-prepares-exit-zero-covid?module=live&pgtype=homepage Nio will increase the inventory of components, monitor workers’ health and adjust its workforce to maintain smooth operations of its Hefei plant, president Qin says

NIO